Venlafaxine Hydrochloride
Product Images NDC 68071-2427

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 68071-2427). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2427 9)

Label for Venlafaxine Hydrochloride 150mg extended-release capsules by NuCare Pharmaceuticals, Inc. The label indicates a package size of 90 capsules. Manufacturer is Anatara Pharma Pvt. Ltd., Telangana, India. The label includes NDC 68071-2427-9 and states 'Rx Only' with storage instructions at controlled temperature 68-77°F.*

FDA Label Image

Figure1 (Figure1)

A chart depicting pharmacokinetic fold changes and 90% confidence intervals for venlafaxine when coadministered with various interacting drugs. The x-axis indicates change relative to a reference value. Recommendations for concomitant use or dose adjustments are shown for each drug interaction, including ethanol, diazepam, cimetidine, ketoconazole, indinavir, metoprolol, imipramine, and lithium.*

FDA Label Image

Figure2 (Figure2)

A forest plot chart illustrating pharmacokinetic fold changes (Cmax and AUC) and 90% confidence intervals for various interacting drugs with Venlafaxine Hydrochloride. The chart includes recommendations regarding dose adjustments or use restrictions for each interacting drug, such as ethanol, diazepam, alprazolam, indinavir, metoprolol, risperidone, imipramine, haloperidol, caffeine, tolbutamide, and lithium, based on changes relative to the reference value.*

FDA Label Image

Figure3 (Figure3)

A dot plot graph showing fold changes and 90% confidence intervals for pharmacokinetic parameters of venlafaxine and its metabolite ODV across special populations, including hepatic impairment (cirrhosis, mild, moderate), renal impairment (mild/moderate, hemodialysis), CYP2D6 polymorphism, age over 60 years, and gender differences. Recommendations for dose adjustments accompany the data for specific populations.*

FDA Label Image

Logo1 (Logo1)

FDA Label Image

Logo2 (Logo2)

FDA Label Image

Venlafaxinestructure (Venlafaxinestructure)

Chemical structure of venlafaxine hydrochloride showing its molecular arrangement, including a chiral center, an aromatic ring with a methoxy group, and a side chain with a hydroxyl group and dimethylamine hydrochloride moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.